Pfizer Inc.: EPS $0.87 vs $0.735 expected; revenue $16.6B vs $15.9B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.870 | 0.735 | +18.4% | 0.870 |
| Revenue (USD bn) | 16.580 | 15.850 | +4.6% | 16.650 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Q3 FY2026 | 0.87 | 0.7350 | +18.4% | 16.58 | 15.85 | +4.6% |
| Aug 4, 2026 | Q2 FY2026 | 0.77 | 0.6820 | +12.9% | 15.03 | 14.40 | +4.4% |
| May 5, 2026 | Q1 FY2026 | 0.75 | 0.7220 | +3.9% | 14.45 | 13.84 | +4.4% |
| Feb 3, 2026 | Q4 FY2025 | 0.66 | 0.5670 | +16.4% | 17.56 | 16.85 | +4.2% |
| Nov 4, 2025 | Q3 FY2025 | 0.87 | 0.6330 | +37.4% | 16.65 | 16.50 | +0.9% |
| Aug 5, 2025 | Q2 FY2025 | 0.78 | 0.5800 | +34.5% | 14.65 | 13.56 | +8.1% |
| Apr 29, 2025 | Q1 FY2025 | 0.92 | 0.6660 | +38.1% | 13.72 | 13.92 | −1.5% |
| Feb 4, 2025 | Q4 FY2024 | 0.63 | 0.4716 | +33.6% | 17.76 | 17.35 | +2.4% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Pfizer Inc. results: EPS $0.87 vs $0.735 expected; revenue $16.6B vs $15.9B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 18.4%; revenue above the estimate by 4.6%.
Revenue was down 0.4% from $16.7 billion a year earlier (Q3 FY2025). EPS was up 0.0% from $0.87 a year earlier. On its record, EPS topped analysts' estimates in 7 of 7 earlier comparable reports.
What the results mean
Shrinking revenue points to pressure on Pfizer’s business, but the available information does not identify the products responsible. Its diverse portfolio makes demand across medicines and vaccines essential to understanding the company’s performance.
Pfizer’s business spans medicines and vaccines across areas including oncology, cardiovascular disease, rare diseases and infections. Its ability to sustain its business depends on developing, marketing and distributing treatments, while product mix and research and development spending remain important drivers of profitability.
What to watch on the earnings call: Investors should follow management’s explanation of the sources of revenue contraction and demand for medicines and vaccines, along with how product mix affects margins. Discussion of research and development priorities, spending and the portfolio’s ability to sustain the business also deserves attention.
For the full analysis of Pfizer Inc. stock — valuation, scores and financial statements — see the stock page linked with this story.